Custirsen does NOT significantly extend survival in men with mCRPC

OncoGenex and Teva stated earlier today that the addition of custirsen (OGX-011) to docetaxel + prednisone did not demonstrate any significant effect on the overall survival of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

OncoGenex gets addditional “fast track” designation for custirsen

According to a media release from OncoGenex, the U.S. Food & Drug Administration has granted a “fast track” designation to the evaluation of data from the so-called AFFINITY trial of custiren + carbazitaxel + prednisone as a second-line treatment for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Results of Phase III trial of custirsen (OGX-011) in mCRPC coming soon

According to a media release issued early this morning by OncoGenex Pharmaceuticals, the Phase III SYNERGY trial of custirsen (originally known as OGX-011) has reached its pre-specified endpoint in terms of the number of events required for final analysis of the trial data. … READ MORE …

Sometimes there is no useful information in that corporate media release

According to a media release issued by OncoGenex Pharmaceuticals earlier today, the Phase III SYNERGY trial of docetaxel + prednisone + custirsen vs. docetaxel + prednisone + a placebo will be “continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC).” … READ MORE …

OncoGenex completes enrollment of patients to Phase III trial of custirsen in mCRPC

Well, it’s taken a little over 2 years, but OncoGenex has completed enrollment of patients into the randomized, double-blind, Phase III SYNERGY trial, which is designed to assess whether the addition of custirsen (OGX-011) to docetaxel-based chemotherapy can extend the survival of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

OncoGenex starts enrollment in new Phase III trial of custirsen

According to a media release from OncoGenex Pharmaceuticals earlier today, the company has started to enroll patients in a second, randomized, Phase III clinical trial of custirsen (OGX-011), this time in combination with second-line chemotherapy. … READ MORE …

OncoGeneX/Teva halt SATURN trial, start new Phase III study with OGX-011

According to a media release from the companies issued yesterday, OncoGeneX and Teva have stopped enrolling patients into the SATURN trial, which was designed to see if OGX-011 (custirsen) could ameliorate bone pain … READ MORE …